Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies

John Carroll

Editor & Founder

Close to 3 years after Vertex helped Arbor Biotechnologies get off the ground with a reputation-building alliance to build gene-editing tools for a suite …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies

John Carroll

Editor & Founder

Sign up to read this article for free.

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Sofinnova outlines $550M fund after IPOs and M&A deals

CagriSema’s weight loss data disappointed. What does Novo do next?

Ver­tex goes back to gene-edit­ing part­ner — and sci­ence founder Feng Zhang — to add $1.2B deal on en­gi­neered cell ther­a­pies

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies

FDA approves subcutaneous version of Bristol Myers' Opdivo

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Sofinnova outlines $550M fund after IPOs and M&A deals

CagriSema’s weight loss data disappointed. What does Novo do next?